tbuckley/cabot-search huggingface dataset:
Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.
Authors: Farhad Ravandi-Kashani, Zeev Estrov, Alessandra Ferrajoli, Gautam Borthakur, Miloslav Beran, Sherry Pierce, Charles A. Koller, Jorge Cortes, Stefan Faderl, Hagop M. Kantarjian
Journal: Blood (2006)
The Consult Guys - Is a Bridge Needed Along This Road?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2016)

Web Exclusives18 October 2016The Consult Guys - Is a Bridge Needed Along This Road?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W16-0010 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Consult Guys bring a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations.For more videos from and information on The Consult Guys, visit www.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Janssen, Portola; Consultancies: Bristol-Myers Squibb, Janssen. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 18 October 2016Volume 165, Issue 8Page: CG1KeywordsDisclosureResearch grantsResearch reporting guidelines ePublished: 18 October 2016 Issue Published: 18 October 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.Loading ...
Evaluation of Prognostic Factors Associated With Differentiated Thyroid Carcinoma With Pulmonary Metastasis
Authors: Mohsen Qutbi, Babak Shafeie, Mahasti Amoui, Faraj Tabeie, Zahra Azizmohammadi, Ali Mahmoud-Pashazadeh, Hamid Javadi, Majid Assadi, Isa Neshandar Asli
Journal: Clinical Nuclear Medicine (2016)

Because one of the major sites for metastasis of thyroid cancers is the lung, studying the pattern of pulmonary metastasis may provide useful information for the effective treatment of these patients. In this study, by assessing the metastasis pattern, we aimed to identify the factors that may affect prognosis and response to treatment in patients with differentiated thyroid carcinoma (DTC) with pulmonary metastasis.This retrospective study included 75 patients with DTC with pulmonary metastasis who were referred to our nuclear medicine section over a period of 10 years. The data obtained were analyzed with regard to response to treatment to assess the effects of the included factors on prognosis.Of the 1746 patients referred to our section, 75 (4.3%) had pulmonary metastasis. According to the pattern of pulmonary metastasis, they were divided into 4 groups: nodular, diffuse, combined, and other. The mean age of the patients was 43.8 ± 18.5 years. After the follow-up, 58 patients survived, 14 of whom responded to the treatment. The mean number of radioiodine therapy sessions that the patients received was 3.2 ± 2, and the mean cumulative dose was 554.7 ± 387.8 mCi. Statistical analysis of the data revealed that there was no significant difference in the response to treatment between patients with different patterns of pulmonary metastasis (P > 0.3). However, significant differences were reported in the response to treatment between patients with papillary thyroid carcinoma and those with follicular thyroid carcinoma (P < 0.03). The 1-, 5-, and 9-year survival rates were reported as 98%, 76%, and 51%, respectively.Patients with DTC with pulmonary metastasis have a relatively favorable prognosis and response rate, as well as longer survival. The type of DTC is the only factor that affects the response to treatment.
GW26-e0757 Inhibitory Effects of Luofengning-0 Formula on the Growth and Proliferation of Human Coronary Artery Smooth Muscle Cells and Endothelial Cells in Vitro: An Exploration of a New Type of Complex Monomer of Chinese Herbs Eluting Stents
Authors: Hongmei Li, Mengqiong Sun, Ang Gao, Zhen Wang, Xueqing Yang, Tian Sun, Changbo Xuan, Xian Wang
Journal: Journal of the American College of Cardiology (2015)
Determinants of Higher Pre-Apheresis CD34+ Count in Patients Undergoing Autologous Hematopoietic Stem Cell Mobilization
Authors: Alexandre Chiattone, Rima M Saliba, Viviane C. Chiattone, XiaoWen Tang, Nelson Hamerschlak, Farzaneh Maadani, Muzaffar H. Qazilbash, Uday Popat, Partow Kebriaei, Richard Champlin, Chitra M Hosing, Marcos DeLima
Journal: Blood (2011)
National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016
Authors: Lia Gvinjilia, Muazzam Nasrullah, David Sergeenko, Tengiz Tsertsvadze, George Kamkamidze, Maia Butsashvili, Amiran Gamkrelidze, Paata Imnadze, Valeri Kvaratskhelia, Nikoloz Chkhartishvili, Lali Sharvadze, Jan Drobeniuc, Liesl Hagan, John W. Ward, Juliette Morgan, Francisco Averhoff
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

The country of Georgia has a high prevalence of hepatitis C virus (HCV) infection, associated with exposures to HCV in health care settings with inadequate infection control and unsafe injections among persons who inject drugs (1). In April 2015, in collaboration with CDC and other partners, Georgia embarked on a program to eliminate HCV infection, subsequently defined as achieving a 90% reduction in prevalence by 2020. The initial phase of the program focused on providing HCV treatment to infected persons with advanced liver disease and at highest risk for HCV-associated morbidity and mortality. By April 27, 2016, a total of 27,392 HCV-infected persons registered for the program, 8,448 (30.8%) started treatment, and 5,850 patients (69.2%) completed HCV treatment. Among patients completing treatment who were eligible for posttreatment testing, 2,398 received polymerase chain reaction (PCR) testing for HCV at least 12 weeks after completion of treatment; 1,980 (82.6%) had no detectable virus, indicative of a sustained virologic response* (i.e., cure). Major challenges to achieving elimination remain, including the need to increase access to care and treatment services and implement a comprehensive approach to prevention and control of HCV infection. As a global leader in this effort, the Georgia HCV Elimination Program can help pave the way for other countries experiencing high rates of HCV infection to undertake similar initiatives.
Abstract IA23: Deconvolution of the triple-negative breast cancer microenvironment
Authors: Sadiq Saleh, Tina Gruosso, Mathieu Gigoux, Nicholas Bertos, Atilla Omeroglu, Dongmei Zuo, Sarkis Meterissian, Michael Hallett, Morag Park
Journal: Cancer Research (2016)

Abstract Breast cancer heterogeneity is one of the principal obstacles both to predicting outcome and to determining an effective course of treatment for this disease. Although genomic technologies have been used to gain a better understanding, by identifying gene expression signatures associated with clinical outcome and breast cancer subtypes, relatively little is known about heterogeneity in the tumor microenvironment. It is now accepted that changes in the normal cells that constitute the tumor microenvironment (TME) play important roles in determining cancer progression and ultimate outcome. We and others have established that an immune gene expression signature correlates with good outcome in triple negative breast cancer (TNBC), yet fails to accurately predict outcome in all patients. Examining stromal heterogeneity in TNBC has identified four distinct stromal clusters, three of which are prognostic, contain distinct immune signatures and a signature of fibrosis. Lymphocytic infiltration and access to tumor parenchyma is not well understood due to high levels of spatial heterogeneity within tumors. We show that location of CD8+T cells is strongly influenced by TME subtypes and identify gene expression signatures predictive of distinct CD8+T cell localization and patient outcome. Since mounting evidence suggests that immune-checkpoint inhibitor immunotherapies may be promising for only a subset of TNBC patients, highlights the importance of understanding how the TME influences CD8+T cell location. Citation Format: Sadiq Saleh, Tina Gruosso, Mathieu Gigoux, Nicholas Bertos, Atilla Omeroglu, Dongmei Zuo, Sarkis Meterissian, Michael Hallett, Morag Park. Deconvolution of the triple-negative breast cancer microenvironment. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr IA23.
Core Outcome Set–STAndards for Reporting: The COS-STAR Statement
Authors: Jamie J. Kirkham, Sarah Gorst, Douglas G. Altman, Jane M. Blazeby, Mike Clarke, Declan Devane, Elizabeth Gargon, David Moher, Jochen Schmitt, Peter Tugwell, Sean Tunis, Paula R. Williamson
Journal: PLoS Medicine (2016)

Background Core outcome sets (COS) can enhance the relevance of research by ensuring that outcomes of importance to health service users and other people making choices about health care in a particular topic area are measured routinely. Over 200 COS to date have been developed, but the clarity of these reports is suboptimal. COS studies will not achieve their goal if reports of COS are not complete and transparent. Methods and Findings In recognition of these issues, an international group that included experienced COS developers, methodologists, journal editors, potential users of COS (clinical trialists, systematic reviewers, and clinical guideline developers), and patient representatives developed the Core Outcome Set–STAndards for Reporting (COS-STAR) Statement as a reporting guideline for COS studies. The developmental process consisted of an initial reporting item generation stage and a two-round Delphi survey involving nearly 200 participants representing key stakeholder groups, followed by a consensus meeting. The COS-STAR Statement consists of a checklist of 18 items considered essential for transparent and complete reporting in all COS studies. The checklist items focus on the introduction, methods, results, and discussion section of a manuscript describing the development of a particular COS. A limitation of the COS-STAR Statement is that it was developed without representative views of low- and middle-income countries. COS have equal relevance to studies conducted in these areas, and, subsequently, this guideline may need to evolve over time to encompass any additional challenges from developing COS in these areas. Conclusions With many ongoing COS studies underway, the COS-STAR Statement should be a helpful resource to improve the reporting of COS studies for the benefit of all COS users.
Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study,
Authors: Jean-Philippe Galanaud, Susan R Kahn, Michael Kovacs, Christina Holcroft, Marisol Betancourt, Philip S Wells, David Anderson, Isabelle Chagnon, Gregoire Le Gal, Susan Solymoss, Mark A. Crowther, Arnaud Perrier, Richard H. White, Linda M Vickars, Tim Ramsay, Marc A. Rodger
Journal: Blood (2011)
Distinct Localization of Coagulation Factor VIII, Von Willebrand Factor and Factor VIIIa-Mimetic Bispecific Antibody Contributing to Thrombus Formation Under Whole Blood Flow Conditions
Authors: Yasuaki Shida, Keiji Nogami, Hiroaki Minami, Hiroaki Yaoi, Tomoko Matsumoto, Takehisa Kitazawa, Kunihiro Hattori, Midori Shima
Journal: Blood (2014)
Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients
Authors: Emma Taylor, Mark Jones, Matthew J Hourigan, David W Johnson, Devinder S Gill, Nicole Isbel, Carmel M Hawley, Paula Marlton, Maher K Gandhi, Scott B Campbell, Peter Mollee
Journal: Blood (2013)
Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103.
Authors: B. P. Schneider, L. Li, K. Miller, D. Flockhart, M. Radovich, B. A. Hancock, N. Kassem, T. Foroud, D. L. Koller, S. S. Badve, Z. Li, A. H. Partridge, A. M. O'Neill, J. A. Sparano, C. T. Dang, D. W. Northfelt, M. L. Smith, E. Railey, G. W. Sledge
Journal: Journal of Clinical Oncology (2011)

1000 Background: Neuropathy, one of the most common toxicities associated with taxane therapy, may be severe, function-limiting, and sometimes irreversible. Established predictors for increased risk include advanced age, diabetes, and type/dose/schedule of taxane. No established biomarkers have been identified to predict patients at greatest risk. Methods: E5103 is a randomized phase III trial comparing standard adjuvant chemotherapy for patients with early stage breast cancer with the same chemotherapy plus concurrent bevacizumab or concurrent and sequential bevacizumab. All 3 arms include weekly paclitaxel for 12 weeks. A GWAS was performed using the Infinium Human Omni1 array on 2204 patients. The primary hypothesis was to identify SNPs associated with time to report of first grade 2−4 neuropathy. SNP data underwent rigorous review to assess both SNP and sample quality. Analyses were performed using Cox regression model including established clinical trial covariates. Bonferroni corrections for multiple comparisons were made. Results: Interim toxicity data from E5103 demonstrated that 613 patients had grade 2−4 neuropathy and 1591 did not. Significant clinical predictors of neuropathy included age (12.9% increase with each 10yrs; p=0.004) and African American race (HR=2.1; p=4.5 ×10−11). Six SNPs with MAF>5% were associated with time to neuropathy (p<5×10−7). These SNPs resided in two genes: RWDD3 and TECTA. A missense SNP in RWDD3 was associated with likelihood of neuropathy at 15 months: 27% for patients with homozygous wild-type, 40% for heterozygous, 60% homozygous variant (allele dose-effect: HR=1.5; p=8.5 ×10−8). A TECTA SNP was associated with likelihood of neuropathy at 15 months: 29% for homozygous wild-type, 32% for heterozygous, and 57% for homozygous variant (recessive-effect: HR=2.1; p=3.2 ×10−7). Multiple other SNPs with MAF<5% were also associated with neuropathy (p<5×10−7). Analysis in the African American subgroup is underway. Conclusions: Using a genome wide approach, we have found several SNPs associated with time to neuropathy in patients undergoing paclitaxel therapy. This is the first time a genetic predictive biomarker has been reported for taxane-induced neuropathy.
Macrocytosis in COPD and Course of the Disease
Authors: Zisis Kontoninas, Fotios Girtovitis, Georgia Kaiafa, George Ntaios, Zoi Saouli, Apostolos Hatzitolios, George Charisopoulos, Christos Savopoulos, Athanasios Papadopoulos
Journal: Blood (2007)
Targeting BTK through microRNA in chronic lymphocytic leukemia
Authors: Arianna Bottoni, Lara Rizzotto, Tzung-Huei Lai, Chaomei Liu, Lisa L. Smith, Rose Mantel, Sean Reiff, Dalia El-Gamal, Karilyn Larkin, Amy J. Johnson, Rosa Lapalombella, Amy Lehman, William Plunkett, John C. Byrd, James S. Blachly, Jennifer A. Woyach, Deepa Sampath
Journal: Blood (2016)
Rapid Activation of Transforming Growth Factor β–Activated Kinase 1 in Chondrocytes by Phosphorylation and K<sup>63</sup>‐Linked Polyubiquitination Upon Injury to Animal Articular Cartilage
Authors: Heba M. Ismail, Athanasios Didangelos, Tonia L. Vincent, Jeremy Saklatvala
Journal: Arthritis & Rheumatology (2016)

Objective Mechanical injury to cartilage predisposes to osteoarthritis (OA). Wounding of the articular cartilage surface causes rapid activation of MAP kinases and NF‐κB, mimicking the response to inflammatory cytokines. This study was undertaken to identify the upstream signaling mechanisms involved. Methods Cartilage was injured by dissecting it from the articular surface of porcine metacarpophalangeal (MCP) joints or by avulsing murine proximal femoral epiphyses. Protein phosphorylation was assayed by Western blotting of cartilage lysates. Immunolocalization of phosphorylated activating transcription factor 2 (ATF‐2) and NF‐κB/p65 was detected by confocal microscopy. Messenger RNA (mRNA) was measured by quantitative reverse transcriptase–polymerase chain reaction (qRT‐PCR). Receptor associated protein 80 (RAP‐80) ubiquitin interacting motif agarose was used in a pull‐down assay to obtain K 63 ‐polyubiquitinated proteins. Ubiquitin linkages on immunoprecipitated transforming growth factor β–activated kinase 1 (TAK‐1) were analyzed with deubiquitinases. Results Sharp injury to porcine cartilage caused rapid activation of JNK and NF‐κB pathways and the upstream kinases MKK‐4, IKK, and TAK‐1. Pharmacologic inhibition of TAK‐1 in porcine cartilage abolished JNK and NF‐κB activation and reduced the injury‐dependent inflammatory gene response. High molecular weight species of phosphorylated TAK‐1 were induced by injury, indicating its ubiquitination. An overall increase in K 63 ‐linked polyubiquitination was detected upon injury, and TAK‐1 was specifically linked to K 63 ‐ but not K 48 ‐polyubiquitin chains. In mice, avulsion of wild‐type femoral epiphyses caused similar intracellular signaling that was reduced in cartilage‐specific TAK‐1–null mice. Epiphyseal cartilage of MyD88‐null and TRAF‐6–null mice responded to injury, suggesting the involvement of a ubiquitin E3 ligase other than TRAF‐6. Conclusion Activation of TAK‐1 by phosphorylation and K 63 ‐linked polyubiquitination by injury indicates its role in driving cell activation. Further studies are needed to identify the upstream ubiquitination mechanisms, including the E3 ligase involved.
New Findings in Ventral Incisional Hernia Repair
Authors: Kamal M. F. Itani
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Subgroup Analysis of Patients Undergoing Autologous and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Deflect-1: A Double-Blind, Randomized Study of Fidaxomicin Vs. Placebo for Prophylaxis Against C. Difficile Infection
Authors: Michael J Dugan, Drew Winston, Michele I Morris, James E Williams, Natasha Broyde, Pamela Sears
Journal: Blood (2015)
Diagnosis by Documentary: Professional Responsibilities in Informal Encounters
Authors: Alistair Wardrope, Markus Reuber
Journal: The American Journal of Bioethics (2016)

Most work addressing clinical workers' professional responsibilities concerns the norms of conduct within established professional-patient relationships, but such responsibilities may extend beyond the clinical context. We explore health workers' professional responsibilities in such "informal" encounters through the example of a doctor witnessing the misdiagnosis and mistreatment of a serious long-term condition in a television documentary, arguing that neither internalist approaches to professional responsibility (such as virtue ethics or care ethics) nor externalist ones (such as the "social contract" model) provide sufficiently clear guidance in such situations. We propose that a mix of both approaches, emphasizing the noncomplacency and practical wisdom of virtue ethics, but grounding the normative authority of virtue in an external source, is able to engage with the health worker's responsibilities in such situations to the individual, the health care system, and the population at large.
In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development
Authors: Alba Azagra, Lidia Román-González, Olga Collazo, Javier Rodríguez-Ubreva, Virginia G. de Yébenes, Bruna Barneda-Zahonero, Jairo Rodríguez, Manuel Castro de Moura, Joaquim Grego-Bessa, Irene Fernández-Duran, Abul B.M.M.K. Islam, Manel Esteller, Almudena R. Ramiro, Esteban Ballestar, Maribel Parra
Journal: The Journal of Experimental Medicine (2016)

Class IIa histone deacetylase (HDAC) subfamily members are tissue-specific gene repressors with crucial roles in development and differentiation processes. A prominent example is HDAC7, a class IIa HDAC that shows a lymphoid-specific expression pattern within the hematopoietic system. In this study, we explored its potential role in B cell development by generating a conditional knockout mouse model. Our study demonstrates for the first time that HDAC7 deletion dramatically blocks early B cell development and gives rise to a severe lymphopenia in peripheral organs, while also leading to pro–B cell lineage promiscuity. We find that HDAC7 represses myeloid and T lymphocyte genes in B cell progenitors through interaction with myocyte enhancer factor 2C (MEFC2). In B cell progenitors, HDAC7 is recruited to promoters and enhancers of target genes, and its absence leads to increased enrichment of histone active marks. Our results prove that HDAC7 is a bona fide transcriptional repressor essential for B cell development.
P0481 : Genome wide mirna: MRNA integrome analysis reveals key pathways, biological processes and gene families in CD4+ T cells that differentiate various stages of HBV infection
Authors: A. Kumar Singh, R. Geffers, S.B. Rooge, A. Varshney, N. Trehanpati, M. Vasudevan, M.K. Sharma, A. Bhardwaj, S.K. Sarin
Journal: Journal of Hepatology (2015)